United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Makes New $811,000 Investment in Amgen Inc. $AMGN

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new position in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,240 shares of the medical research company’s stock, valued at approximately $811,000.

Other large investors have also recently made changes to their positions in the company. Cornerstone Select Advisors LLC grew its stake in shares of Amgen by 8.2% during the 2nd quarter. Cornerstone Select Advisors LLC now owns 4,743 shares of the medical research company’s stock valued at $1,718,000 after acquiring an additional 359 shares during the period. Fort Sheridan Advisors LLC raised its position in shares of Amgen by 0.9% during the second quarter. Fort Sheridan Advisors LLC now owns 8,505 shares of the medical research company’s stock valued at $3,080,000 after buying an additional 72 shares during the last quarter. Cane Capital Partners LLC increased its holdings in Amgen by 73.2% in the 2nd quarter. Cane Capital Partners LLC now owns 3,259 shares of the medical research company’s stock valued at $1,180,000 after acquiring an additional 1,377 shares during the last quarter. Kinsale Capital Group Inc. lifted its position in shares of Amgen by 12.2% in the second quarter. Kinsale Capital Group Inc. now owns 42,075 shares of the medical research company’s stock worth $15,236,000 after buying an additional 4,564 shares in the last quarter. Finally, Mosaic Family Wealth Partners LLC raised its holdings in shares of Amgen by 71.0% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 2,977 shares of the medical research company’s stock worth $1,078,000 after acquiring an additional 1,236 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 1.0%

NASDAQ AMGN opened at $419.38 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $421.79. The firm has a market capitalization of $226.73 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 3.86 and a beta of 0.41. The company has a fifty day moving average of $372.05 and a two-hundred day moving average of $359.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts predict that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last 90 days. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. UBS Group upped their target price on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein lifted their price target on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group boosted their price objective on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $372.39.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.